ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Osteoporosis

Osteoporosis

New in the New England Journal: Romosozumab, whose target is sclerostin, increased BMD more than teriperatide and alendronate in a phase 2 trial involving postmenopausal women. Also, a puzzle: A rheumatic cause of abdominal pain.

The FDA has approved Duavee, the first medication to combine estrogen with bazedoxifene, for the treatment of hot flashes and the prevention of osteoporosis after menopause.

Wholesale vitamin D supplementation may not prevent osteoporosis, judges a review of clinical trials. Other news: A novel drug that directly targets IL-6 up for regulatory scrutiny, newfound mutations in Sjögren's syndrome, and why eczema itches.

Results from the Framingham Ostoporosis Study show that change in bone mineral density over baseline offers little predictive value. Also last week: More support for diet and exercise to reduce the pain of knee OA.

New in the general journals: A chart review suggests rethinking recommendations about monitoring osteoporosis treatments. Also: Stroke as a presenting symptom for fungus-infected spinal injections, and more ...

Multidetector-row computed tomography made changes in bone microarchitecture visible among bisphosphonate-treated patients with glucocorticoid-induced osteoporosis.

Post-menopausal women taking less than the standard 5 mg dose of zoledronate did just as well on bone density and turnover measures, according to a randomized trial.

Pages

Subscribe to Osteoporosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.